Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Нервные болезни
2019 / N 3

Патогенетические подходы к терапии хронической цереброваскулярной недостаточности
А.Н. Боголепова

References

1. Gusev EI, Bogolepova AN. Cognitive impairment in cerebrovascular diseases. Moscow: Medpress-inform; 2013. 160 p. (In Russian).
2. Skvortsova VI, Stakhovskaya LV, Gudkova VV, Alekhin AV. Chronic cerebrovascular insufficiency. In: Neurology. National guidance. Gusev EI, Konovalova AN, Skvortsova VI, editors. 2nd ed. Moscow: Geotar-Media; 2018. 836 p. (In Russian).
3. Gusev EI, Chukanova AS. Modern pathogenetic aspects of chronic cerebral ischemia formation. Korsakov SS Journal of Neurology and Psychiatry 2015;115(3):4-8 (In Russian).
4. Zlokovic BV. Neurovascular mechanisms of Alzheimer’s neurodegeneration. Trends in Neurosciences 2005 Apr;28(4):202-8.
5. Magaki SD, Williams ChK, Vinters HV. Glial function (and dysfunction) in the normal & ischemic brain. Neuropharmacology 2018 May;134(Pt B):218-25.
6. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008 Jan;57(2):178-201.
7. Muoio V, Persson PB, Sendeski MM. The neurovascular unit – concept review. Acta Physiologica (Oxford, England) 2014 Apr;210(4):790-8.
8. Dobrynina LA. Neurovascular coupling and cerebral perfusion in aging, cerebral microangiopathy and Alzheimer’s disease. Annals of Clinical and Experimental Neurology 2018;12(Special issue):87-94 (In Russian).
9. Toole JF, Gusev EI, Gekht AB, Bogolepova AN. Lacunar syndromes and hypertensive encephalopathy. In: Toole JF. Cerebrovascular disorders. 6th ed. Moscow: Geotar-Media; 2007: 375-93 (In Russian).
10. Ham PB 3rd, Raju R. Mitochondrial function in hypoxic ischemic injury and influence of aging. Progress in Neurobiology 2017 Oct;157:92-116.
11. Shaik S, Wang Z, Inuzuka H, Liu P, Wei W. Endothelium aging and vascular diseases. IntechOpen 2013 Feb 20. DOI: 10.5772/53065.
12. Cai W, Zhang K, Li P, Zhu L, Xu J, Yang B, Hu X, Lu Z, Chen J. Dysfunction of the neurovascular unit in ischemic stroke and neurodegenerative diseases: an aging effect. Ageing Research Reviews 2017 Mar;34:77-87.
13. Lo EH, Rosenberg GA. The neurovascular unit in health and disease: introduction. Stroke 2009 Mar;40(3 Suppl):S2-3.
14. Sohrabji F, Bake S, Lewis DK. Age-related changes in brain support cells: implications for stroke severity. Neurochemistry International 2013 Oct;63(4):291-301.
15. Kasatkin DS. A neurovascular unit as a point of action of some vasoactive and neuroprotective drugs. Korsakov SS Journal of Neurology and Psychiatry 2012;112(9):103-7 (In Russian).
16. Lokshina AB, Zakharov VV. Practical algorithms of management of patients with chronic cerebral ischemia. Effective Pharmacotherapy 2019;15(19):24-8 (In Russian).
17. Starchina YuA, Zakharov VV. Non-demential cognitive impairment: the role of neurometabolic therapy. Effective Pharmacotherapy. Neurology and Psychiatry 2017;31:8-19 (In Russian).
18. Gromova OA, Torshin IYu, Kalacheva AG, Semenov VA, Rudakov KV. MexiB 6 as a result of fortification of ethylmethylhydroxypyridine succinate with magnesium and pyridoxine: proteome effects. Neurology, Neuropsychiatry, Psychosomatics 2016;8(4):38-44 (In Russian).
19. Hruby A, O’Donnell CJ, Jacques PF, Meigs JB, Hoffmann U, McKeown NM. Magnesium intake is inversely associated with coronary artery calcification: the Framingham Heart Study. JACC Cardiovascular Imaging 2014 Jan;7(1):59-69.
20. Gromova OA, Torshin IYu, Rudakov KV, Grustlivaya UE, Kalacheva AG, Yudina NV, Egorova EYu, Limanova OA, Fedotova LE, Gracheva ON, Nikiforova NV, Satarina TE, Gogoleva IV, Grishina TR, Kuramshina DB, Novikova LB, Lisitsyna EYu, Kerimkulova NV, Vladimirova IS, Chekmareva MN, Lyalyakina EV, Shalayeva LA, Taleporovskaya SYu, Siling TB, Semenov VA, Semenova OV, Nazarova NA, Galustyan AN, Sardaryan IS. Magnesium deficiency is a significant risk factor for comorbid conditions: results of large-scale screening of magnesium status in Russian regions. Farmateka 2013;6:16-28 (In Russian).
21. Gromova OA, Torshin IYu, Fedotova LE, Gromov AN. Chemoreactome analysis of ethylmethylhydroxypyridine succinate. Neurology, Neuropsychiatry, Psychosomatics 2016;8(3):53-60 (In Russian).
22. Bogolepova AN, Burd SG, Fris YaE. Combined therapy in patients with chronic cerebral ischemia. Korsakov SS Journal of Neurology and Psychiatry 2018;118(8):33-7 (In Russian).
23. Tucek S. Choline acetyltransferase and the synthesis of acetylcholine. In: The cholinergic synapse. Handbook of experimental pharmacology. Whittaker VP, editor. Berlin, Heidelberg: Springer; 1988: 125-65.
24. Bogolepova AN. Circadian rhythm disorders and their drug correction in Alzheimer’s disease. Psychiatry and Psychopharmacotherapy 2009;11(4):13-6.
25. Traini E, Bramanti V, Amenta F. Choline alphoscerate (alpha-glyceryl-phosphoryl-choline) an old choline-containing phospholipid with a still interesting profile as cognition enhancing agent. Current Alzheimer Research 2013 Dec;10(10):1070-9.
26. Tayebati SK, Amenta F, Tomassoni D. Cerebrovascular and blood-brain barrier morphology in spontaneously hypertensive rats: effect of treatment with choline alphoscerate. CNS & Neurological Disorders-Drug Targets 2015;14(3):421-9.
27. Parnetti L, Amenta F, Gallai V. Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data. Mechanisms of Ageing and Development 2001 Nov;122(16):2041-55.
28. De Jesus Moreno Moreno M. Cognitive improvement in mild to moderate Alzheimer’s dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. Clinical Therapeutics 2003;25(1):178-93.
29. Arakelyan GV, Sturov NV. Efficacy of choline alfoscerate in cerebrovascular disorders. Fundametal Research 2006;1:22 (In Russian).
30. Lee SH, Choi BY, Kim JH, Kho AR, Sohn M, Song HK, Choi HC, Suh SW. Late treatment with choline alfoscerate (l-alpha glycerylphosphorylcholine, α-GPC) increases hippocampal neurogenesis and provides protection against seizure-induced neuronal death and cognitive impairment. Brain Research 2017 Jan;1654(Pt A):66-76.
31. Bogolepova AN. Current approaches to cerebrovascular pathology treatment: ways to increase adherence. Practical Medicine 2014;2(78):136-40 (In Russian).
32. Kovalenko EA, Bogolepova AN. Pre-stroke cognitive impairment and its impact on medication adherence. Neurology, Neuropsychiatry, Psychosomatics 2018;10(2):63-7 (In Russian).
33. Zakharov VV. Vinpotropil in the treatment of dyscirculatory encephalopathy with cognitive impairment without dementia. Korsakov SS Journal of Neurology and Psychiatry 2010;110(11):13-6 (In Russian).
34. Filimonov VA, Klyueva VN, Kondrashova IN. Vinpotropil in the treatment of vascular diseases of the brain. Korsakov SS Journal of Neurology and the Psychiatry 2007;2:58-60 (In Russsin).
  

[ Содержание выпуска N 3 | Выпуски журнала | Список журналов ]